Infections

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Warts

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Pharmaceutical Solutions

All Drugs and Chemicals

A-101 Topical Solution

A-101 Vehicle Solution

The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.

The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.

The secondary objectives of this study are to evaluate the clinical effect of A-101 when applied to all treated warts (Target Warts plus Non-Target Warts), duration of response in all treated warts (Target Warts plus Non-Target Warts), and Safety of A-101.

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts

Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated.

1. Near Clear: A visible wart that is less than 3 mm in maximal diameter (or length)
2. A visible wart ≥ 3 mm and \< 6 mm in maximal diameter (or length)
3. A visible wart ≥ 6 mm in maximal diameter (or length)

Aclaris Therapeutics, Inc.

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation subject administered a study medication(s) and that did not necessarily have a causal relationship with the study medication.

Safety summaries by study medication group will include listings by study medication of adverse events incidences within each MedDRA System Organ Class, and changes from pre-application values in vital signs.

A-101 Topical Solution

A-101 Topical Solution: A-101 Topical Solution

Active

Vehicle

A-101 Topical Solution: A-101 Topical Solution

Vehicle

Total

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Executive Director, Clinical Operations

Mean Change in Physician's Wart Assessment Score From Baseline to Day 57

Overall Study

Spots Global Cancer Trial Database for A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial